Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers

C. Lindsay DeVane, John S. Markowitz, Stanley W. Carson, David W. Boulton, Harry S. Gill, Ziah Nahas, S. Craig Risch

Research output: Contribution to journalArticlepeer-review

30 Scopus citations

Abstract

Six adults phenotyped as either extensive (N = 4) or poor (N = 2) metabolizers for cytochrome P450 (CYP) 2D6 were given a 10-mg oral dose of methylphenidate (MPH) on two separate occasions with and without quinidine, a potent CYP2D6 inhibitor. Quinidine had no significant effect on the pharmacokinetics of either MPH or ritalinic acid, its major metabolite, in either group of CYP2D6 metabolizers. These data suggest a lack of involvement of CYP2D6 in the metabolism of MPH. Drugs that are inhibitors of CYP2D6 when taken concurrently with MPH should not affect its plasma concentration.

Original languageEnglish (US)
Pages (from-to)347-349
Number of pages3
JournalJournal of Clinical Psychopharmacology
Volume20
Issue number3
DOIs
StatePublished - Jun 1 2000

Fingerprint Dive into the research topics of 'Single-dose pharmacokinetics of methylphenidate in CYP2D6 extensive and poor metabolizers'. Together they form a unique fingerprint.

Cite this